Salt Lake City, UT Clinical Trials Report — April 2026

For Salt Lake City residents considering participation in clinical research, April 2026 presents a timely opportunity to explore studies nearing their enrollment deadlines. Across the city, 55 clinical trials are scheduled to conclude within the next 90 days. This includes 6 trials that are still actively seeking healthy volunteers, offering a chance for individuals without specific health conditions to contribute to medical advancements before these opportunities close.

Urgent Opportunities: Trials Closing Soon

Patients with specific health conditions should note the trials with impending deadlines. Conditions with studies closing soon include:

• Heart failure (2 trials)
• Stage IVB prostate cancer AJCC V8 (2 trials)
• Acute lymphoblastic leukemia (2 trials)
• Advanced NSCLC (1 trial)
• Astrocytoma (1 trial)
• Advanced solid tumor (1 trial)
• Acute undifferentiated leukemia (1 trial)
• ALS - Amyotrophic Lateral Sclerosis (1 trial)
• Alzheimer disease (1 trial)
• Asthma (1 trial)

This month, Salt Lake City saw the opening of 11 new clinical trials, a slight decrease from the 14 trials that launched in March 2026. Despite this, the city remains a significant hub for medical research, with a total of 879 clinical trials currently recruiting across 263 research facilities.

Spotlight on New Research Opportunities

April brings several notable new trials to Salt Lake City, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments for various health challenges.

• Incyte Corporation is sponsoring NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy for metastatic pancreatic cancer.
• Carelon Research is launching NCT07525843, "A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study." This study aims to determine if an online wellbeing program can help teens with congenital heart disease improve their ability to handle stress, targeting 390 participants.
• Boehringer Ingelheim is initiating NCT07544654, "A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy." This Phase 3 study is open to adults with advanced extrapulmonary neuroendocrine cancer and seeks 390 participants to compare a new treatment combination against standard chemotherapy.
• Eli Lilly and Company is leading NCT07511816, "A Study of LY4515100 in Participants With Pain Following Third Molar Removal." This Phase 2 study will evaluate the safety and efficacy of LY4515100 for acute postsurgical pain after wisdom tooth removal, involving 212 participants.
• Jazz Pharmaceuticals is sponsoring NCT07533942, "A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma." This Phase 2 study will recruit 30 participants with recurrent meningiomas who have failed prior therapy to evaluate the antitumor activity and safety of JZP3507.
• The University of Utah is sponsoring NCT07548450, "Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)." This Phase 2 trial aims to test the safety and tolerability of a combination of study drugs in 25 patients with relapsed or refractory Waldenstrom's Macroglobulinemia.

New trials this month are exploring conditions such as acute pain, adolescent congenital heart disease, CML (refractory and relapsed), concussion, diffuse large B cell lymphoma, meningioma, and mild traumatic brain injury. The majority of new studies, 9 of them, are drug trials, with one behavioral and one device trial also opening.

Healthy Volunteers and Participation Demographics

While only 0 of the 11 new trials launched this month are accepting healthy volunteers, Salt Lake City still offers 79 total clinical trials currently recruiting healthy participants. These opportunities allow individuals without specific medical conditions to contribute significantly to medical research.

Participation in clinical trials is open to a diverse range of individuals. Of the new trials launched this month, 2 include children and 8 include older adults, ensuring that various age groups have opportunities to contribute to medical science. No new trials are exclusively for female or male participants this month.

Salt Lake City's Research Hubs

Salt Lake City is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Utah (188 trials)
• Huntsman Cancer Institute/University of Utah (82 trials)
• Huntsman Cancer Institute (63 trials)
• Primary Children's Hospital (63 trials)
• Huntsman Cancer Institute, University of Utah (29 trials)
• University of Utah Health (23 trials)
• Huntsman Cancer Institute at University of Utah (18 trials)
• University of Utah Sugarhouse Health Center (18 trials)
• LDS Hospital (16 trials)
• Research Site (14 trials)
• Huntsman Cancer Institute at the University of Utah (14 trials)
• University of Utah Hospital (14 trials)

The University of Utah system, including its various affiliated centers like the Huntsman Cancer Institute and Primary Children's Hospital, clearly leads the research landscape in Salt Lake City, offering a broad spectrum of studies across many medical fields.

Broadening Your Search: Nearby Options

While Salt Lake City offers a wide array of clinical trial opportunities, individuals may also find options in nearby communities within Utah. Cities with active trials include South Jordan (3 trials), Cedar (1 trial), Sandy City (1 trial), Syracuse (1 trial), and West Valley City (1 trial). These nearby options provide additional avenues for participation for those willing to travel a short distance.

As we move further into spring, the focus will remain on the ongoing enrollment in these significant Phase 2 and Phase 3 trials and the continued exploration of new therapeutic strategies, with Salt Lake City's robust research community at the forefront of medical innovation.